Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide analysis of gene expression from islets of different sizes in response to in vivo serpin B13 mAB treatment

ABSTRACT: By using oligonucleotide microarray-based technology as a tool for rapid mapping of unique differences in gene expression, we found that inhibiting serpin B13 in BALB/c mice treated with a mAb according to our protocol resulted in the upregulation of relatively few genes, including several Reg genes, which have been implicated in β-cell proliferation.

ORGANISM(S): Mus musculus

PROVIDER: GSE125151 | GEO | 2019/03/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide analysis of gene expression from islets of different sizes in response to in vivo serpin B13 mAB treatment

Project description:Genome-wide analysis of gene expression from islets of different sizes in response to in vivo serpin B13 mAB treatment

| PRJNA515333 | ENA

Norepinephrine inhibits CD8+ T cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma

Project description:BACKGROUND:Mental stress-induced neurotransmitters can affect the immune system in various ways, leading to tumor immune escape. Therefore, a better understanding of the potential functions of neurotransmitters in the tumor immune microenvironment is expected to promote the development of novel anti-tumor therapies, while facilitating synergistic immune therapy. METHODS: In this study, we analyzed the plasma levels of neurotransmitters in anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb)-resistance patients and sensitive patients, to identify significantly different neurotransmitters. Subsequently, animal experiments, transcriptome analysis, metabolomic analysis, and experiments in vitro were used to reveal the specific mechanism of norepinephrine’s (NE) effect on immunotherapy. RESULTS: The plasma NE levels were higher in anti-PD-1 mAb-resistance patients, which may be the main cause of anti-PD-1 mAb resistance. An animal model was established for verification, which further demonstrated that NE could cause anti-PD-1 mAb resistance. Then, from the perspective of the immunosuppressive microenvironment to explore the specific mechanism of NE-induced anti-PD-1 mAb resistance, we found that NE can affect the secretion of the C-X-C Motif Chemokine Ligand 9 (CXCL9) and the immunosuppressive metabolite adenosine (ADO) in tumor cells, thereby inhibiting chemotaxis and function of CD8+ T cells. Notably, the WNT7A/β-catenin signaling pathway plays a crucial role in the NE-induced decrease in the secretion of CXCL9 and disturbance of ADO metabolism. CONCLUSION: NE can affect the secretion of CXCL9 and ADO in tumor cells, thereby inhibiting chemotaxis and the function of CD8+ T cells and inducing anti-PD-1 mAb resistance in lung adenocarcinoma (LUAD).

2023-04-04 | GSE218402 | GEO

Brucella sp. MAB-22

Project description:Brucella sp. MAB-22 Genome sequencing and assembly

| PRJNA890377 | ENA

Coolia malayensis strain:MAB

Project description:Coolia malayensis strain:MAB Transcriptome or Gene expression

| PRJNA541782 | ENA

Identification of transcription factor MAB-5 binding sites

Project description:We identified the DNA binding sites of MAB-5 in C. elegans. MAB-5 was C-terminally tagged with GFP and the expression pattern was examined through fluorescent microscopy. The binding sites were determined using chromatin immunoprecipitation with anti-GFP antibody followed by illumina high-throughput sequencing (ChIP-seq). For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf Identification of MAB-5 binding sites at L3 stage

2009-04-11 | E-GEOD-15625 | biostudies-arrayexpress

Effect of CLDN1 mAb on primary patient derived liver organoids

Project description:Organoids were established from non-tumorous cirrhotic liver tissue and treated with CLDN1 mAb or Control mAb for 4 days. Organoids were harvested and mRNA was extracted. RNAsequencing was performed for comparative gene expression profiling.

2024-03-12 | GSE206581 | GEO

The effect of ANGPTL3 mAb on liver transcriptomes in LDLR-deficient mice

Project description:Purpose: The goal of this study was to evaluate the effect of ANGPTL3 inhibition on liver transcriptomes in LDLR KO mice. Methods: Mice were treated once weekly for 3 weeks with 25mg/kg control mAb or ANGPTL3 mAb. Livers were harvested 6 days after the last mAb treatment. Results: ANGPTL3 inhibition had no major impact on hepatic gene expression.

2020-07-05 | GSE143726 | GEO

A randomized Phase II study comparing SOX+B-mab with SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with KRAS wild type.

Project description:Interventions: A group (SOX+B-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. B-mab is administered intravenously in 7.5 mg/kg by tri-weekly. B group (SOX+C-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. C-mab is administered intravenously in 400 mg/m2 on day 1, then 250 mg/m2 weekly thereafter. Or C-mab is administered intravenously in 500 mg/m2 by bi-weekly. Primary outcome(s): Response rate Study Design: Parallel Randomized

| 2622133 | ecrin-mdr-crc

Transcriptomic data of B-cell lymphoma bearing mice treated with anti-CD20/-CD27 mAb therapy

Project description:We report the single-cell RNA sequencing data obtained from BCL1 lymphoma-bearing mice treated with either isotype control, anti-CD20 mAb, anti-CD27 mAb or anti-CD20+anti-CD27 mAb together

2018-01-12 | GSE97037 | GEO

Identification of transcription factor MAB-5 binding sites

2009-04-11 | GSE15625 | GEO